002262 恩华药业
已收盘 10-30 15:00:00
资讯
新帖
简况
恩华药业（002262）10月26日主力资金净卖出929.05万元
证券之星 · 10-27
恩华药业（002262）10月26日主力资金净卖出929.05万元
恩华药业（002262）2026年三季报简析：营收净利润同比双双增长
证券之星 · 10-25
恩华药业（002262）2026年三季报简析：营收净利润同比双双增长
恩华药业(002262)9月30日股东户数4.7万户，较上期减少11.93%
证券之星 · 10-23
恩华药业(002262)9月30日股东户数4.7万户，较上期减少11.93%
图解恩华药业三季报：第三季度单季净利润同比下降0.01%
证券之星 · 10-23
图解恩华药业三季报：第三季度单季净利润同比下降0.01%
恩华药业(002262.SZ)发布前三季度业绩，归母净利润11.46亿元，同比增长3.63%
智通财经 · 10-23
恩华药业(002262.SZ)发布前三季度业绩，归母净利润11.46亿元，同比增长3.63%
股市必读：恩华药业新发布《关于参股公司Good Mood Holdings Limited增资的公告》
证券之星 · 09-30
股市必读：恩华药业新发布《关于参股公司Good Mood Holdings Limited增资的公告》
恩华药业（002262）发布关于签署独占许可协议暨对外投资的公告，9月29日股价下跌0.23%
证券之星 · 09-29
恩华药业（002262）发布关于签署独占许可协议暨对外投资的公告，9月29日股价下跌0.23%
恩华药业最新公告：授予Somnivera一款在研创新药独家权利有权获最高5.07亿美元里程碑付款
证券之星 · 09-29
恩华药业最新公告：授予Somnivera一款在研创新药独家权利有权获最高5.07亿美元里程碑付款
恩华药业：与Somnivera签订独占许可协议 有权获最高5.07亿美元里程碑付款
格隆汇 · 09-29
恩华药业：与Somnivera签订独占许可协议 有权获最高5.07亿美元里程碑付款
恩华药业（002262）9月24日主力资金净卖出1643.06万元
证券之星 · 09-28
恩华药业（002262）9月24日主力资金净卖出1643.06万元
股市必读：恩华药业新发布《关于完成工商变更及备案登记手续并换发营业执照的公告》
证券之星 · 09-28
股市必读：恩华药业新发布《关于完成工商变更及备案登记手续并换发营业执照的公告》
恩华药业（002262）披露完成工商变更及备案登记手续并换发营业执照公告，9月23日股价上涨0.73%
证券之星 · 09-23
恩华药业（002262）披露完成工商变更及备案登记手续并换发营业执照公告，9月23日股价上涨0.73%
恩华药业：创新药开发是企业的希望与未来
证券之星 · 09-21
恩华药业：创新药开发是企业的希望与未来
国药控股与恩华药业签署新一轮战略合作协议
同花顺 · 09-10
国药控股与恩华药业签署新一轮战略合作协议
股市必读：恩华药业（002262）9月3日董秘有最新回复
证券之星 · 09-04
股市必读：恩华药业（002262）9月3日董秘有最新回复
恩华药业：公司销售模式是采用赊销方式
证券之星 · 09-03
恩华药业：公司销售模式是采用赊销方式
股市必读：恩华药业新发布《关于部分限制性股票回购注销完成的公告（1）》
证券之星 · 08-28
股市必读：恩华药业新发布《关于部分限制性股票回购注销完成的公告（1）》
恩华药业（002262）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-19
恩华药业（002262）2026年中报简析：营收净利润同比双双增长
恩华药业(002262)6月30日股东户数5.34万户，较上期增加23.8%
证券之星 · 08-18
恩华药业(002262)6月30日股东户数5.34万户，较上期增加23.8%
恩华药业：NMPA批准NH302注射液及NH130枸橼酸盐片临床试验
美股速递 · 08-18
恩华药业：NMPA批准NH302注射液及NH130枸橼酸盐片临床试验
加载更多
公司概况
公司名称：
江苏恩华药业股份有限公司
所属行业：
医药制造业
上市日期：
2008-07-23
主营业务：
江苏恩华药业股份有限公司的主营业务是医药研发、生产和销售。公司的主要产品是原料药、麻醉类制剂、精神类制剂、神经类制剂。公司荣获“2026年度资信等级AAA”、“2026中国医药创新企业100强”、“2026化药研发实力20强”、“2026药品研发综合实力50强”等荣誉，恩华络康被纳入火炬企业库，恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。
发行价格：
5.68
{"stockData":{"symbol":"002262","market":"SZ","secType":"STK","nameCN":"恩华药业","latestPrice":21.61,"timestamp":1793343810000,"preClose":21.2,"halted":0,"volume":10813338,"delay":0,"changeRate":0.0193,"floatShares":884000000,"shares":1013000000,"eps":1.0835,"marketStatus":"已收盘","change":0.41,"latestTime":"10-30 15:00:00","open":21.2,"high":21.8,"low":21.01,"amount":233000000,"amplitude":0.0373,"askPrice":21.62,"askSize":55,"bidPrice":21.61,"bidSize":118,"shortable":0,"etf":0,"ttmEps":1.0835,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":21.2,"symbolType":"stock","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":23.32,"lowLimit":19.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1012971423,"isCdr":false,"pbRate":2.44,"roa":"--","peRate":19.944624,"roe":"13.56%","epsLYR":1.05,"committee":-0.181753,"marketValue":21890000000,"turnoverRate":0.0122,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-02。","floatMarketCap":19098000000},"requestUrl":"/m/hq/s/002262","defaultTab":"news","newsList":[{"id":"2678143621","title":"恩华药业（002262）10月26日主力资金净卖出929.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678143621","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678143621?lang=zh_cn&edition=full","pubTime":"2026-10-27 09:06","pubTimestamp":1793063215,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月26日收盘，恩华药业报收于22.44元，上涨3.55%，换手率1.69%，成交量14.96万手，成交额3.34亿元。10月26日的资金流向数据方面，主力资金净流出929.05万元，占总成交额2.78%，游资资金净流出1034.3万元，占总成交额3.09%，散户资金净流入1963.34万元，占总成交额5.87%。近5日资金流向一览见下表：恩华药业融资融券信息显示，融资方面，当日融资买入1964.76万元，融资偿还2121.28万元，融资净偿还156.52万元。恩华药业主营业务：医药研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700011325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2148510915.USD","BK0070","LU1064130708.USD","002262","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678974185","title":"恩华药业（002262）2026年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2678974185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678974185?lang=zh_cn&edition=full","pubTime":"2026-10-25 06:07","pubTimestamp":1792879661,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩华药业发布2026年三季报。根据财报显示，恩华药业营收净利润同比双双增长。截至本报告期末，公司营业总收入47.76亿元，同比上升6.81%，归母净利润11.46亿元，同比上升3.63%。按单季度数据看，第三季度营业总收入15.57亿元，同比上升6.61%，第三季度归母净利润4.05亿元，同比下降0.01%。本文数据来源于恩华药业2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500000532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677928375","title":"恩华药业(002262)9月30日股东户数4.7万户，较上期减少11.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677928375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677928375?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:58","pubTimestamp":1792749484,"startTime":"0","endTime":"0","summary":"证券之星消息，近日恩华药业披露，截至2026年9月30日公司股东户数为4.7万户，较6月30日减少6368.0户，减幅为11.93%。在化学制药行业个股中，恩华药业股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年6月30日至2026年9月30日，恩华药业区间涨幅为21.23%，在此期间股东户数减少6368.0户，减幅为11.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300032711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1064131003.USD","BK0239","LU2148510915.USD","BK0070","BK0188","002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677460940","title":"图解恩华药业三季报：第三季度单季净利润同比下降0.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677460940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677460940?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:46","pubTimestamp":1792748763,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业2026年三季报显示，前三季度公司主营收入47.76亿元，同比上升6.81%；归母净利润11.46亿元，同比上升3.63%；扣非净利润11.59亿元，同比上升4.59%；其中2026年第三季度，公司单季度主营收入15.57亿元，同比上升6.61%；单季度归母净利润4.05亿元，同比下降0.01%；单季度扣非净利润4.14亿元，同比上升1.06%；负债率11.48%，投资收益5302.22万元，财务费用-636.23万元，毛利率71.67%。财报数据概要请见下图:本文数据来源于恩华药业2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300032183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677941471","title":"恩华药业(002262.SZ)发布前三季度业绩，归母净利润11.46亿元，同比增长3.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677941471","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677941471?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:27","pubTimestamp":1792744026,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)发布2026年第三季度报告，公司前三季度实现营业收入47.76亿元，同比增长6.81%;归属于上市公司股东的净利润11.46亿元，同比增长3.63%;归属于上市公司股东的扣除非经常性损益的净利润11.59亿元，同比增长4.59%;基本每股收益1.14元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671244486","title":"股市必读：恩华药业新发布《关于参股公司Good Mood Holdings Limited增资的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671244486","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671244486?lang=zh_cn&edition=full","pubTime":"2026-09-30 02:59","pubTimestamp":1790708347,"startTime":"0","endTime":"0","summary":"公司公告汇总：参股公司Good Mood Holdings Limited拟增资2.62亿元，公司放弃优先认缴权，持股比例由19.0960%降至18.0454%。公司公告汇总关于参股公司Good Mood Holdings Limited增资的公告江苏恩华药业股份有限公司公告，其参股公司Good Mood Holdings Limited（好心情）拟增资262,000,000.00元，配发股份777.4744万股，由安杰睦德、爱美客、无锡鼎祺、漳州市九龙江、漳州高鑫、山金资产管理及Unifuture共同认购。作为对价的一部分，恩华药业通过全资子公司香港恩华获得Somnivera公司15%股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000002792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","LU1064130708.USD","LU1064131003.USD","BK0239","LU2148510915.USD","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671484622","title":"恩华药业（002262）发布关于签署独占许可协议暨对外投资的公告，9月29日股价下跌0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671484622","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671484622?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:33","pubTimestamp":1790692397,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，恩华药业报收于21.5元，较前一交易日下跌0.23%，最新总市值为217.79亿元。近日，江苏恩华药业股份有限公司与Somnivera, Inc.签署独占许可协议，将其自主研发的1类创新药在除中国大陆及港澳台地区以外的全球范围内开发、生产和商业化的独家权利授予Somnivera。作为对价的一部分，恩华药业通过全资子公司香港恩华获得Somnivera公司15%股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900040599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","002262","LU1064130708.USD","LU2148510915.USD","BK0188","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671215693","title":"恩华药业最新公告：授予Somnivera一款在研创新药独家权利有权获最高5.07亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2671215693","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671215693?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:39","pubTimestamp":1790678395,"startTime":"0","endTime":"0","summary":"恩华药业(002262.SZ)公告称，公司与Somnivera签订独占许可协议，授予其在除中国大陆、港澳台外的全球范围开发、生产和商业化一款在研药物独家权利。该在研药物是公司自主研发、具有自主知识产权的1类创新药，拟用于治疗睡眠障碍。Somnivera将支付首付款1050万美元，公司有权获最高5.07亿美元里程碑付款，以及按净销售额的一位数至低双位数百分比计算的分层特许权使用费。公司另通过全资子公司香港恩华获Somnivera15%股权。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900032706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","002262","159992","BK1161","BK0070","BK0239","BK1574","06978","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671621586","title":"恩华药业：与Somnivera签订独占许可协议 有权获最高5.07亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2671621586","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671621586?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:37","pubTimestamp":1790678273,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0188","BK0070","BK0239","002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670077984","title":"恩华药业（002262）9月24日主力资金净卖出1643.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670077984","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670077984?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:27","pubTimestamp":1790558822,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，恩华药业报收于21.16元，下跌3.82%，换手率0.91%，成交量8.01万手，成交额1.72亿元。9月24日的资金流向数据方面，主力资金净流出1643.06万元，占总成交额9.54%，游资资金净流入2662.69万元，占总成交额15.47%，散户资金净流出1019.63万元，占总成交额5.92%。近5日资金流向一览见下表：恩华药业融资融券信息显示，融资方面，当日融资买入988.46万元，融资偿还1040.26万元，融资净偿还51.8万元。恩华药业主营业务：医药研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800003007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0188","BK0070","LU2148510915.USD","LU1064131003.USD","002262","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409596","title":"股市必读：恩华药业新发布《关于完成工商变更及备案登记手续并换发营业执照的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409596","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409596?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:24","pubTimestamp":1790529853,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，恩华药业报收于21.16元，下跌3.82%，换手率0.91%，成交量8.01万手，成交额1.72亿元。当日关注点交易信息汇总：9月24日主力资金净流出1643.06万元，占总成交额9.54%。公司公告汇总：恩华药业于9月23日完成注册资本变更及《公司章程修正案》备案登记，取得换发营业执照，注册资本由101,578.6583万元变更为101,297.1423万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","LU1064131003.USD","LU1064130708.USD","BK0239","002262","LU2148510915.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669102852","title":"恩华药业（002262）披露完成工商变更及备案登记手续并换发营业执照公告，9月23日股价上涨0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669102852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669102852?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:39","pubTimestamp":1790156380,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘，恩华药业报收于22.0元，较前一交易日上涨0.73%，最新总市值为222.85亿元。近日，恩华药业发布《关于完成工商变更及备案登记手续并换发营业执照的公告》。公告显示，公司于2026年9月17日向徐州市政务服务管理办公室申请办理变更公司注册资本及《公司章程修正案》备案登记手续。公司注册资本由变更前的101,578.6583万元整变更为101,297.1423万元整。除上述变更外，其他登记事项未发生变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300030761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU1064130708.USD","BK0239","BK0070","LU2148510915.USD","BK0188","002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669253155","title":"恩华药业：创新药开发是企业的希望与未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2669253155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669253155?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:54","pubTimestamp":1789977253,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：公司业务目前面临新旧动能切换，并且出海还在初步，请问未来公司各大板块发展战略优先级是新药还是出海？恩华药业回复：根据战略规划，公司业务发展有着清晰的路径和可持续的动能支持。创新药开发是企业的希望与未来，目前促进创新药在国内落地是第一要务；同时，国际化也是公司战略目标之一，出海是公司长期愿景，是跟随产品管线不断完善的后手布局，公司一直在积极探索开拓国际市场。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100016467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","LU2148510915.USD","002262","BK0239","06978","LU1064130708.USD","BK0188","BK1574","BK1161","LU1064131003.USD","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666556434","title":"国药控股与恩华药业签署新一轮战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2666556434","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666556434?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:40","pubTimestamp":1789033200,"startTime":"0","endTime":"0","summary":"近日，国药控股与恩华药业在上海举行战略合作沟通会，双方以“同行致远 共赴新程”为主题，围绕准入协同、商销一体化、零售终端等方向深入交流，并签署新一轮战略合作协议。国药控股党委副 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260910/c679790430.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260910/c679790430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","002262","BK0070","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664806846","title":"股市必读：恩华药业（002262）9月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2664806846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664806846?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:44","pubTimestamp":1788457455,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，恩华药业报收于22.6元，上涨0.44%，换手率0.63%，成交量5.59万手，成交额1.26亿元。董秘最新回复投资者： 董秘好，我想了解下公司应收账款占比这么高，请问公司销售模式是赊销方式吗？账期都是多长时间？客户性质不同，账期有所不同。当日关注点交易信息汇总：9月3日主力资金净流入328.04万元，占总成交额2.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","LU1064131003.USD","LU1064130708.USD","BK0188","002262","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820046","title":"恩华药业：公司销售模式是采用赊销方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664820046?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:54","pubTimestamp":1788425648,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)09月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，我想了解下公司应收账款占比这么高，请问公司销售模式是赊销方式吗？账期都是多长时间？恩华药业回复：公司应收账款的销售占比与同类公司同口径比较而言基本相当，反映了公司所处行业的销售回款现状。目前，公司销售模式是采用赊销方式。客户性质不同，账期有所不同。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300030395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0188","BK0070","BK0239","002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662803820","title":"股市必读：恩华药业新发布《关于部分限制性股票回购注销完成的公告（1）》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662803820","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662803820?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:14","pubTimestamp":1787861653,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，恩华药业报收于22.02元，下跌0.5%，换手率0.8%，成交量7.07万手，成交额1.55亿元。当日关注点交易信息汇总：8月27日主力资金净流出616.57万元，占总成交额3.98%。公司公告汇总：恩华药业完成281.5160万股限制性股票回购注销，总股本由101,578.6583万股减至101,297.1423万股。回购价格为10.75元/股，回购原因为部分激励对象离职或退休，以及公司2025年度业绩未达股权激励计划第二个解除限售期的考核目标。本次回购注销不影响公司经营成果和股权分布上市条件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800009021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","LU2148510915.USD","LU1064131003.USD","002262","BK0239","BK0188","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660859490","title":"恩华药业（002262）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2660859490","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660859490?lang=zh_cn&edition=full","pubTime":"2026-08-19 06:08","pubTimestamp":1787090887,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩华药业发布2026年中报。根据财报显示，恩华药业营收净利润同比双双增长。截至本报告期末，公司营业总收入32.18亿元，同比上升6.91%，归母净利润7.41亿元，同比上升5.74%。持有恩华药业最多的基金为华夏复兴混合A，目前规模为15.71亿元，最新净值2.816，较上一交易日上涨0.43%，近一年上涨24.88%。本文数据来源于恩华药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900004076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660465980","title":"恩华药业(002262)6月30日股东户数5.34万户，较上期增加23.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660465980","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660465980?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:28","pubTimestamp":1787045328,"startTime":"0","endTime":"0","summary":"证券之星消息，近日恩华药业披露，截至2026年6月30日公司股东户数为5.34万户，较3月31日增加1.03万户，增幅为23.8%。在化学制药行业个股中，恩华药业股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.64万户。从股价来看，2026年3月31日至2026年6月30日，恩华药业区间跌幅为14.61%，在此期间股东户数增加1.03万户，增幅为23.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","LU1064130708.USD","BK0188","LU2148510915.USD","LU1064131003.USD","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194623670","title":"恩华药业：NMPA批准NH302注射液及NH130枸橼酸盐片临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1194623670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194623670?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:57","pubTimestamp":1787025428,"startTime":"0","endTime":"0","summary":"恩华药业宣布，其自主研发的NH302注射液与NH130枸橼酸盐片已获得国家药品监督管理局（NMPA）的临床试验批准。这一进展标志着公司在创新药物研发领域迈出了关键一步。两项药物均处于临床开发早期阶段，未来将针对特定适应症展开系统评估。此次获批不仅凸显了恩华药业在神经精神类药物领域的持续深耕，也为后续产品管线推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","BK0239","002262","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793475598563,"stockEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":-0.0493},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0167},{"period":"1year","weight":-0.0913},{"period":"ytd","weight":-0.0865}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恩华药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47010人(较上一季度减少11.93%)","perCapita":"18799股","listingDate":"2008-07-23","address":"江苏省徐州市鼓楼区经济技术开发区杨山路18号","registeredCapital":"101297万元","survey":" 江苏恩华药业股份有限公司的主营业务是医药研发、生产和销售。公司的主要产品是原料药、麻醉类制剂、精神类制剂、神经类制剂。公司荣获“2026年度资信等级AAA”、“2026中国医药创新企业100强”、“2026化药研发实力20强”、“2026药品研发综合实力50强”等荣誉，恩华络康被纳入火炬企业库，恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。","listedPrice":5.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩华药业,002262,恩华药业股票,恩华药业股票老虎,恩华药业股票老虎国际,恩华药业行情,恩华药业股票行情,恩华药业股价,恩华药业股市,恩华药业股票价格,恩华药业股票交易,恩华药业股票购买,恩华药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}